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Abstract: A goal of the 3rd phase of the Electronic Medical Records and Genomics (eMERGE3)
Network was to examine the return of results (RoR) of actionable variants in more than 100 genes to
consenting participants and their healthcare providers. Each of the 10 eMERGE sites developed plans
for three essential elements of the RoR process: Disclosure to the participant, notification of the health
care provider, and integration of results into the electronic health record (EHR). Procedures and
protocols around these three elements were adapted as appropriate to individual site requirements
and limitations. Detailed information about the RoR procedures at each site was obtained through
structured telephone interviews and follow-up surveys with the clinical investigator leading or
participating in the RoR process at each eMERGE3 institution. Because RoR processes at each of the
10 sites allowed for taking into account differences in population, disease focus and institutional
requirements, significant heterogeneity of process was identified, including variability in the order in
which patients and clinicians were notified and results were placed in the EHR. This heterogeneity
in the process flow for eMERGE3 RoR reflects the “real world” of genomic medicine in which RoR
procedures must be shaped by the needs of the patients and institutional environments.
Keywords: genomic medicine; genetic testing; return of results; electronic health record

1. Introduction
Decreasing costs of DNA sequencing, coupled with an increasing understanding of the human
genome, are some of the driving forces behind the acceleration of genomic medicine [1–3]. Genomic
sequencing is more frequently being performed to diagnose rare disorders, to individualize cancer
treatments, and inform drug selection and dosing, as well as to screen for disease susceptibility and
carrier status for recessive conditions [4–6]. As a result, patients with “medically actionable” conditions
and predispositions are being identified, either as a primary findings from clinical testing, or as
unanticipated secondary findings unrelated to the initial indication that prompted the sequencing
tests [7,8]. In some cases, these results are not specifically ordered or requested by the patients’
healthcare providers (HCPs), who may be unclear about their obligations to interpret and respond to
these “unsolicited” findings [9,10].
The rapid pace of testing has led to the current healthcare climate, where patients and their
HCPs are increasingly confronting the potential healthcare implications of unanticipated incidental
or unsolicited genomic sequencing results [9,11]. The American College of Medical Genetics and
Genomics (ACMG) has recommended that conditions associated with a minimum set of 59 genes are
sufficiently actionable to be returned to the HCP regardless of the testing indication [12,13]. However,
there is no standard practice for returning these types of results from genomic studies to patients,
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research participants, HCPs, or the health care system. Yet, many have argued that individuals should
have the opportunity to learn their actionable genetic results along with referral for appropriate clinical
follow up [14].
The NIH has sponsored many initiatives to evaluate use of genomics in healthcare, including
the Clinical Sequencing Exploratory/Evidence-Generating Research (CSER) Consortium, Clinical
Genomic Resource (ClinGen), Implementing Genomics in Practice (IGNITE) network and the electronic
Medical Record and Genomics (eMERGE) Network [15–18]. Among these, the eMERGE Network is
addressing the implementation of genomic medicine within the US healthcare system [18]. Established
more than 10 years ago, the primary goal of the network has been “to develop, disseminate, and
apply approaches to research that combine biorepositories with electronic medical record systems for
genomic discovery and genomic medicine implementation research” [19]. Now in the third phase
of funding (eMERGE3), the Network consists of 10 clinical sites and 2 sequencing centers across the
US. It is focused on sequencing of 109 medically relevant genes, 14 pharmacogenetic (PGx) variants,
and additional medically relevant single nucleotide variants (SNVs), in approximately 25,000 study
participants [20]. An essential goal of eMERGE3 is the intentional return of results (RoR) of clinically
actionable variants to the consenting participants and their HCPs from a curated set of genes and to
incorporate those results into the electronic health record (EHR).
There is currently no protocol or practice standards for returning unsolicited genetic tests that are
identified as a consequence of clinical care or research programs. eMERGE3 emulates the “real world”
of genomic medicine today, in which organizations are independently exploring incorporation of
genomics into clinical practice, and provides an ideal setting to study the RoR processes for genomic
sequence results that were not solicited by HCPs in a diverse set of healthcare institutions. This paper
describes the planned RoR processes independently developed at each of the 10 eMERGE3 sites and
examines the similarities and differences in approaches for the disclosure of unsolicited genomic results
to participants and their HCPs in order to identify “best practices” for the utilization and return of
genomic information within the healthcare system today.
2. Materials and Methods
2.1. Study Setting
As part of eMERGE3, each site developed plans for (1) disclosing genetic results to patients,
(2) disclosing genetic results to HCPs, and (3) incorporating the result in the EHR. The processes
and procedures for these elements of RoR were adapted as necessary to individual site context,
population, and institutional requirements. Information about the intended RoR processes and
protocols was collected from the 10 participating eMERGE3 sites, including Cincinnati’s Children’s
Hospital and Medical Center (CCHMC), Children’s Hospital of Philadelphia (CHOP), Columbia
University (CU), Geisinger (GE), Kaiser Permanente of Washington (KPWA, formerly Group Health
Cooperative)/University of Washington (UW), Mayo Clinic (MC), Meharry Medical College (MMC),
Northwestern University (NU), Partners HealthCare (PHC), and Vanderbilt University Medical Center
(VUMC) (Table 1). eMERGE3 methods have been described elsewhere [20,21], but briefly, participants
were recruited via bio-repositories, health clinics or community settings.
Participant DNA samples were analyzed using the eMERGEseq next generation sequencing
platform at either the Partners HealthCare Laboratory for Molecular Medicine (LMM) or the Baylor
College of Medicine Human Genome Sequencing Center (HGSC) Clinical Laboratory, both of which
are Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologist
(CAP) certified. A minimal set of clinically actionable and returnable genes was determined by expert
consensus within the eMERGE Network that consisted of a core set of 68 genes with the addition
of genes as designated by each site [20]. The eMERGEseq platform included genes recommended
for secondary findings disclosure by the ACMG [12,13], as well as additional genes selected by each
site based on research interest such as additional colorectal cancer, cardiovascular, or kidney disease
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genes [20]. The initial platform was designed to include the “ACMG 56” set, and was later expanded to
include 58 of the 59 genes currently recommended by ACMG [13]. Also included were other medically
relevant SNVs, including PGx SNVs.
Table 1. Planned enrollment and participant descriptors for 10 sites in the electronic Medical Record
and Genomics (eMERGE) network.
Target (n)

Source of
Participant 1

Age Group

Enriched
Population

Enriched Disease Phenotype

2800

Biorepository

Pediatric

None

None

200 2

Clinic,
community

Adolescent

None

None

3000

Biorepository

Adult
(young)
Pediatric

None

Autism, ADHD

500

Community

Adult

Ashkenazi
Jewish,
Hispanic

None

1000

Clinic,
Community

Adult

None

Renal disease, liver disease
and cancer

1000

Biorepository

Adult

None

Renal disease, liver disease
and cancer

GE 3

2500

Biorepository

Adult

None

Some tested in research
study prior

KPWA/UW

2500

Biorepository

Adult

None

Colorectal polyps and cancer

500

Clinic

Adult

Asian

None

2500

Biorepository

Adult

None

Hypercholesterol- emia and
colon polyps

500

Biorepository

Adult

Hispanic

Dyslipidemia

500

Clinic

Adult

AfricanAmerican

Cancer, or family history of lung,
breast, prostate, or colon cancer

NU

3000

Clinic,
PGx
Biorepository

Adult

None

Lipid disorders, atrial
fibrillation, breast cancer,
ovarian cancer screening,
dermatology

PHC

2500

Biorepository

Adult

None

None

VUMC 4

2500

Primary care
clinic, PGx
Biorepository

Adult

None

None

Site

CCHMC

CHOP

CU

MC

MMC

1 # Source of participant: Biorepository, Clinic, Community Randomized Trial (RTC). Partial enrollment from
previous biorepository research study for 2 randomized trial of parent-adolescent dyads, 3 whole exome sequencing,
4 pharmacogenetic (PGx).

Positive results of the genomic tests (i.e., pathogenic (P) or likely pathogenic (LP); rare variants
with presumed major impact on the function of these genes [22]) were slated to be returned to those
participants who had consented to receive their eMERGE3 results, their HCPs, and incorporated into
the EHR according to each site’s RoR process. The EHR integration has been described [23] where
structured results from laboratories were transferred to the site using sFTP and an HTTPS-based Simple
Storage Service (S3) file transfer provided by DNAnexus [20]. An open source an XML structured
result format was developed which was informed by Health Level 7 (HL7) standards. A PDF file was
created for each report that was also uploaded to the participants medical record at the eMERGE site.
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For the purposes of this manuscript, the RoR process is described after the clinical center receives
sequencing report from the molecular laboratory.
2.2. Study Analysis
Telephone interviews were conducted by one author (GLW) with the clinical investigator leading or
participating in the RoR process at each eMERGE3 institution who had direct and intimate knowledge
about the process. Information was obtained for over 30 different factors across the continuum
of the RoR process for each eMERGE site. Sites were additionally asked to create a flow diagram
of their RoR protocol; several sites had different processes dependent on the age, recruitment or
demographic of the population. These flow diagrams were analyzed for sequential order of events,
method of RoR communication, such as letter, phone call or clinic appointments, and who disclosed
the results to participants. Follow-up information was obtained by surveying the eMERGE RoR
Workgroup regarding development of the site’s protocols, and whether there were unanticipated
events or alterations that impacted the actual RoR process compared to the initial RoR plan.
Factors identified through the data collection were categorized into one of the three elements
relating to the RoR disclosure to the participant at the site, notifying the HCP, or uploading the
information to the EHR. Additional descriptors included the demographics of the eMERGE3
participants, the genes and variants that could potentially be released in the genetic test report,
the specialty/subspecialty of the provider who would disclose the result to the participant and the
timing of the disclosure. Recognizing that both the participant and the HCP need to be informed about
the results, the term disclosure is used here to indicate how the participant would be informed about the
genetic test result, the term notification to indicate how the HCP would be informed about the result,
and upload or integration to indicate how the eMERGRE3 report would be placed in the participant’s
EHR. HCP is defined in this study as a non-genetic practitioner who has a clinical relationship with the
participant, such as primary care provider, non-genetic medical specialist or nurse practitioner.
3. Results
3.1. Participant Population Characteristics
Similar to the current state of the “real world” of genomic medicine today, in which organizations
are independently exploring incorporation of genomics into clinical practice, eMERGE3 sites varied
in the recruitment and type of participant enrolled for eMERGE3. To date, each site has enrolled
between 500–3000 participants for the eMERGE3 project with a total population of approximately
25,000 participants undergoing sequencing using the eMERGEseq platform. Five of the 10 sites drew
samples from both biorepositories and participants recruited specifically for eMERGE3, four sites drew
samples from biorepositories only, and one site recruited participants entirely from medical center
clinics. Consent for the project was obtained at different time points, including as part of enrollment to
the eMERGE study or to an existing biorepository, or when a result was to be released to the participant.
The eMERGE3 study population represents all age groups, with two sites enrolling pediatric participants.
Table 1 summarizes the expected number of participants, whether the participants were recruited
from clinic or samples from an existing biorepository were used, whether they were pediatric or adult
participants, and whether the site targeted any specific ancestry/ethnic group or disease phenotype.
3.2. Genes Included in RoR
All sites developed plans to return results from a core set of 68 genes on the eMERGEseq platform,
however, sites could choose additional genes and types of variants to return since, by design, each site
independently developed the RoR processes based on their populations [20]. For example, in addition
to the core set of genes, MC returned variants from additional genes related to cardiovascular disease,
KPWA/UW returned variants from additional genes related to colon cancer, CU returned variants from
additional genes related to kidney disorders, and CU targeted arm added genes causing pediatric
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autosomal recessive disorders for carrier screening associated with reproductive risks. The sites that
enrolled pediatric participants (CCHMC and CHOP) chose to exclude the return of variants in genes
associated with adult onset orders, such as breast or colon cancer, from the RoR, except for an adolescent
(CCHMC) sub-study participants in which results for some adult onset disorders were offered [24].
One site (PHC) planned to confine RoR to only variants found in the ACMG list of designated genes.
While all 10 sites planned to return P/LP actionable results to their participants [22], sites differed
in their plans for the return of variant of uncertain significance (VUS), P/LP heterozygous carriers for
autosomal recessive conditions, PGx results, and results without identified P/LP variants, labeled as
“negative” or “no variant identified” results (Table 2); thus creating additional variability in the RoR
process. Only one site planned to return VUS to a subset of their consenting participants (KPWA/UW).
The KPWA/UW site planned to return VUS in mismatch repair genes to participants affected by colon
cancer or colon polyps, with subsequent immunohistochemistry (IHC) testing of the tumor tissue if
available. Five sites planned to return PGx variants to all or some participants, including a subset
of the CCHMC cohort (an adolescent-parent dyad sub-study by participant request), pediatric and
adult participants at CHOP, and adult participants at GE, NU and VUMC. Results with no actionable
finding (i.e., no P/LP variants in the reportable genes) were planned to be returned to consenting
adolescent-parent dyads in the CCHMC sub-study by participant request and to consenting adult
participants enrolled at CU, MC, NU, KPWA/UW, and VUMC sites.
Table 2. Type of gene variant planned for disclosure to eMERGE3 participants who consented for RoR
by eMERGE site. All sites planned to return pathogenic (P) or likely pathogenic (LP) variants.
Site

Participants

Pediatric—
Biorepository
CCHMC

CHOP

Disclosure

Adult onset
disorder genes
excluded
1

By

Variant Disclosure to Participant
P/LP

VUS

Carrier

Pharma

No
Variant

GC

Yes

No

No

No

No

Yes

Yes

Adolescent—
Clinic, community

All, by
participant
request, RTC

GC
or EHR
portal

Yes

No

Yes

Adults—
Biorepository

All

GC

Yes

No

No

2

Pediatric—
Biorepository

Adult onset
disorder genes
excluded

GC

3

Yes

No

No

2,3

PAR
choice

4

Yes

No

Yes

No

Adults—Targeted
arm (Clinic, and
community)

4

All

Yes

No

Yes

No

4

Yes

Adults— General
arm (Clinic, and
community)

All

GC

Yes

No

No

No

Yes

Adults—
Biorepository

Re-confirmed

GC

Yes

No

No

No

No

GE

Adults—
Biorepository

All

GC

Yes

No

No

Yes

No

KPWA/UW

Adults—
Biorepository and
clinic

All

GC

Yes

Yes

No

No

Yes

CU
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Table 2. Cont.
Site

Participants

Disclosure

By

Variant Disclosure to Participant
P/LP

VUS

Carrier

Pharma

No
Variant

Adults—
Biorepository

All

GC

Yes

No

No

No

Yes

Adults—Clinic

All

GC

Yes

No

No

No

Yes

MMC

Adults— Clinic

All cancer
genes and
participant’s
choice for
other genes

GC

Yes

No

No

No

No

NU

Adults—
Biorepository

All

GC

Yes

No

No

No

Yes

Adults—Clinic

All

GC

Yes

No

No

Yes

Yes

No

No

No

No

No

No

MC

5

PHC

Adults—
Biorepository

Re-confirmed

PAR
choice

VUMC

Adults—PGx
and Clinic

All

Letter

4

Yes

Yes

2

Yes

6

Yes

Key: Disclosure by a Genetic Counselor (GC), participant (PAR), Healthcare provider (HCP), Letter, or EHR
(Electronic Health Record). Sites that enrolled participants: 1 Randomized Controlled Trial (RTC) with choices for
return; 2 Pharmacogenetic variants are uploaded to EHR, and returned by letter; 3 Participant choice of type of
variant (P/LP or PGx) at time of consent; 4 Participant choice after discussion with GC (non-RTC); 5 Initial notification
of P/LP by GC, but final result disclosed by participant choice; 6 Letter sent to participant.

One site planned to return results based on sub-study randomization (CCHMC), and two sites
allowed participant request (CCHMC, CU). One site (CU-targeted arm) planned to return either P/LP,
carrier results or no variant results according to the preferences of participants queried at the time of
enrollment. The CCHMC had an adolescent-parent dyad sub-study which planned to return carrier
results for selected autosomal recessive conditions by participant request [24]. Further, this group
could also choose to learn 14 SNVs primarily related to inborn errors of metabolism as well as some
PGx results mentioned previously.
3.3. RoR Disclosure Processes
Each eMERGE site independently developed plans for RoR that included three essential
components: (1) Disclosure of the results to the participant, (2) notification of the HCP of the
result, and (3) integration of the genomic results into the EHR. However, the sites’ plans differed in
timing and order of these components, following one of three pathways (Table 3). Five sites intended
to disclose the results to the participants first, then notify the HCP followed by upload to the EHR.
Three sites intended to disclose the results to the participant first, then upload to the EHR, and notify
the HCP. Two sites intended to upload to the EHR first, then notify the provider, and then disclose
the results to the participant. Thus, the most common first step in the process was disclosure of the
sequencing results to the participant (eight of 10 sites), followed by notification of the HCP and then
inclusion in the participant’s EHR (Table 3). Eight sites planned to disclose to the participant as the
initial step, and the 2 remaining sites planned to upload to the Electronic Health Record (EHR). Seven
sites planned to notify to the healthcare provider (HCP) as the second step.
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Table 3. Order of eMERGE3 site return of results (RoR) for participants consented to return of
actionable results.
Number

Sites

First Step

Second Step

Third Step

5
3
2

CHOP, PHC 1 , KPWA/UW 1 , MMC, NU
CCHMC 1,2 , CU 1 , MC
GE 3 , VUMC

Participant
Participant
EHR

HCP
EHR
HCP

EHR
HCP
Participant

Key: Healthcare provider (HCP), Electronic health record (EHR). 1 Site allowing participants to decline RoR. For CU,
the participants in the biorepository arm could decline learning their results. 2 Site planned a RTC option to upload
to EHR, notify HCP prior to disclosing to participant. 3 Concurrent upload to EHR and HCP notification.

The eMERGE3 sites developed different RoR processes to communicate results with the participants.
Importantly, for the return of positive (P/LP) results, all sites planned to have genetic professionals,
either a genetic counselor or geneticist, as either the initial disclosing professional (CCHMC, CHOP,
MC, MMC, NU, KPWA/UW), non-genetic specialist or geneticist after the initial disclosure by letter
(VUMC), by participant choice at enrollment (CCHMC, CU, GE), or participant choice after learning of
an unconfirmed positive result (PHC). One site (CU-targeted arm) planned to conduct sub-study of
return that allowed the participant to specify the method of return, such as phone, letter, secure email,
or clinic visit. Most sites (CU, CHOP, CCHMC, KPWA/UW, MC, MMC, NU, PHC) planned to contact
the participant initially by a letter or a phone call indicating the need for the participant to schedule an
appointment with a professional specializing in the results of that gene or their HCP to receive the
results. Most sites indicated that they use multiple communication formats, including letter, telephone
and/or clinic visits for disclosure and participant communication, with two sites (CCHMC, GE) also
planning to use the EHR patient portal. Five sites developed protocols that allowed participants to opt
out of receiving all or some of their results (CU-targeted, CCHMC, CHOP, KPWA/UW, PHC).
3.4. EHR Integration
Participant reports were integrated into the medical record of the participant by uploading a PDF
file. Most sites (8 of 10) elected to upload the report as the last step in the return process. Due to
technical issues, structured formatted report data remained in the research data repositories [23].
Several sites identified participants with more than one reportable variant, which required some sites
(KPWA/UW, CHOP, VUMC) to manually add additional variant interpretations into the EHR.
4. Discussion
The design and structure of the eMERGE3 RoR research network fostered a natural experiment;
reflecting the “real world” of genomic medicine today where there are no best practice guidelines
and where institutions create processes specific to their organizational structures, populations, and
providers. The eMERGE3 network seeks the analysis of up to 100 clinically actionable genes and
14 SNVs of about 25,000 participants across 10 different clinical sites, and requires three elements of
return of these results (1) disclosure of the results to the participant, (2) notification of the HCP of
the result, and (3) integration of the genomic results into the EHR. Sites were free to choose which
genes to return, whether to return VUS and/or “negative” results, and the processes by which return
would happen based on their population and institutional requirements and limitations. By analyzing
the planned RoR processes, this study describes the complexity and process variation of returning
“unsolicited” genomic results to the eMERGE research participants who consented to result disclosure.
Three general pathways were identified across the 10 eMERGE3 sites to deliver the 3 required
elements of RoR; with the majority of sites choosing to disclose the genomic results first to the
participant and then to notify the HCP. The clinical sites also varied in which additional genes were
interrogated and type of variants chosen to disclose to the participants and their HCPs. By design,
all eMERGE sites returned P/LP variants in a core set of genes, but differed as to whether to return
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P/LP variants in additional genes, VUS, carrier state for recessive conditions, or potential mosaicism
(Table 2).
Our study results reflect an underlying perception that genetic professionals should be engaged
in the RoR process, as 8 of 10 sites planned to have either a genetic counselor or geneticist be the
initial provider to disclose the positive results to their participants. This mirrors the experience
of other studies, such as CSER study that provided return of secondary findings from genome or
exome sequencing from diverse healthcare settings using genetic professionals [15,25]. Concern has
been raised, however, about the clinical workforce capacity with the limited number of geneticists
and genetic counselors and the much larger number of patients requiring genetic services in the
future [26–28]. How, and by whom, such results are to be returned is extremely important, particularly
in light of the launch of the precision medicine All of Us research project, where up to a million US
citizens will undergo genomic testing with disclosure of actionable risk information in the next few
years [29].
The traditional model of genetic professionals providing initial disclosure of results will not be
scalable in the future, necessitating the development of alternative programs for communicating test
results. Studies examining the use of primary care providers in returning results have had promising
results [25]. However, it may not be feasible to shift the responsibility for managing genomic test
results to primary care providers or other specialists as research has shown that the current HCP
workforce lacks the capacity and knowledge to interpret genetic results and manage the disease states
linked to actionable gene variants [30,31]. A related eMERGE study has reported that HCPs also have
concerns for returning unsolicited results which include lack of knowledge to interpret the test report
and negative impact on clinical workflow [9]. Alternative methods for reporting genomic results are
being investigated by several groups using web-based informatic technology for patient education [32],
and use of telemedicine using video or telephone for counseling [33–35].
As genomic testing expands with more clinical and direct to consumer laboratories offering
different genomic health screens [7], these diverse initial eMERGE RoR experiences described here
can be used as a foundation to better understand the underlying contextual factors, organizational
culture, and norms around genomic medicine. Here we have outlined the planned RoR processes
as adapted by each of the 10 eMERGE3 sites to address the required elements of (1) disclosing to
patients, (2) notifying providers, and (3) integrating the result into the EHR and the additional real-time
adjustments to these processes in response to unplanned events early on in the testing process. As the
RoR study progresses, the “lessons learned” from the RoR processes at each site will inform current
eMERGE3 investigations and other precision medicine projects examining the impact of the RoR on
medical outcomes, health care usage, participants and HCPs. For example, a comparative analysis of
the three identified RoR processes will be important in understanding the clinical utility, management
and institutional resources required for RoR. This will provide further insight into which RoR elements
and processes must be considered regardless of organizational context and which processes work best
within different institutional structures.
5. Conclusions
There is currently no standard of practice for returning unsolicited genetic and genomic data
to patients or research participants. This report on initial ROR processes and experiences across 10
eMERGE3 sites highlights the current real-world needs of healthcare systems in developing new
pathways to support genomic medicine. By focusing on the required elements of RoR and describing
how sites developed processes and procedures to adapt those elements within their unique contexts,
we provide the foundation for studying within eMERGE3 and other future studies the impact of these
RoR processes on patient, provider, and organization utilization of genomic information.
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